PharmaShots | Incisive News in 3 Shots

Subscribe Now

Mirum

Mirum’s Livmarli Receives Health Canada Authorization for Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum’s Livmarli Receives Health Canada Authorization for Cholestatic Pruritus in Patients with Alagille Syndrome

July 27, 2023

Mirum Published Results of Livmarli (maralixibat) for the Treatment of Alagille Syndrome in Hepatology

Mirum Published Results of Livmarli (maralixibat) for the Treatment of Alagille Syndrome in Hepatology

June 15, 2023

Mirum Submits Application to the EMA for Marketing Authorization of Livmarli for Progressive Familial Intrahepatic Cholestasis

Mirum Submits Application to the EMA for Marketing Authorization of Livmarli for Progressive Familial Intrahepatic Cholestasis

April 6, 2023

Mirum’s Livmarli (maralixibat) Receives the Label Expansion Approval from the US FDA for Alagille Syndrome in Infants Aged ≥3 Months

Mirum’s Livmarli (maralixibat) Receives the Label Expansion Approval from the US FDA for Alagille Syndrome in Infants Aged ≥3 Mont...

March 15, 2023

Mirum Reports sNDA Submission to the US FDA for Livmarli (maralixibat) to Treat Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Reports sNDA Submission to the US FDA for Livmarli (maralixibat) to Treat Cholestatic Pruritus in Progressive Familial Intra...

February 15, 2023

Mirum’s Livmarli (maralixibat) Receives EMA’s CHMP Positive Opinion for Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum’s Livmarli (maralixibat) Receives EMA’s CHMP Positive Opinion for Cholestatic Pruritus in Patients with Alagille Syndrome

October 17, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us